Vernalis collaborates with a wide range of organisations to enable drug discovery programs through both short- and long-term projects. By applying our deep and wide expertise in structure-based drug discovery, built over twenty-five years of partnerships and innovation to enable challenging targets, we can express and engineer your proteins, find and validate hits and help to evolve your chemical series into pre-clinical candidates. And we can do all this in-house at our fully equipped laboratories in Cambridge UK.
More about usWe combine fragment based methods, DNA Encoded Library (DEL) technology, Medium-Throughput biochemical screening (MTS), virtual screening and knowledge-based approaches to identify robust hit series. With our extensive experience, we have a deep understanding of the need for well-validated chemical matter and multiple backup series. At the heart of our approach is innovation, using our experience to overcome challenges and to deliver hits, leads and candidates to our partners.
Vernalis has collaborated with a wide range of partners to enable some of the most challenging therapeutic targets. Present and past collaborators include Servier, Pierre Fabre, Genentech and Lundbeck. Vernalis can support programs with DEL and fragment-based technologies through to establishing full drug discovery programmes for our partners. We can provide protein production, hit identification and validation through to lead optimisation, cellular biology and DMPK. Collaboration structures vary from long term, multi target projects through to short discrete pieces of work.
Speaker: Ben Davis
